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dence from clinical studies concerning the relative effectiveness
of Fluad® and non-adjuvanted vaccines in the over 65 popula-
tion. Evidence concerning the impact of Fluad® on hospitalisa-
tion was taken from an observational study, other resource use
parameters and costs from the literature. The analysis was per-
formed from the payer perspective (direct medical costs).
RESULTS: Based on the increased protective efﬁcacy of Fluad®
compared to non-adjuvanted vaccines, we estimated a reduction
in cases of between 11.8% and 23.8% depending on the inﬂuenza
strain circulating in the community. Using these estimates, for an
attack rate of Inﬂuenza-like Illness of 5% and a discount rate of
3%, the incremental cost per life year gained (CLYG) ranged from
€3103 to €23,894. In situations where there is antigenic drift
(which occurs every 2–5 years), all vaccines are less effective.
However, the efﬁcacy of Fluad® falls by only 2%, whereas that
of non-adjuvanted vaccines falls by 22%. With antigenic drift,
the cost-effectiveness of Fluad® compared to non-adjuvanted vac-
cines is enhanced due to the better protective effect, and depend-
ing on the circulating strain, ranged from being cost saving to an
incremental CLYG of €5709. CONCLUSION: Compared to non-
adjuvanted vaccines, Fluad® is cost-effective. Since the estimated
cost per life year gained is within acceptable thresholds, Fluad®
should be used as the vaccine of choice in older people. * Fluad®
is registered under the trade name Gripguard® in France.
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OBJECTIVES: To evaluate the cost-effectiveness of three differ-
ent immunization strategies (1st: one time routine vaccination of
all adolescents aged 11 years [yr], 2nd: college freshmen aged 18
yr, and 3rd: college freshmen living in dormitories aged 18 yr)
with meningococcal polysaccharide (serogroups A, C, Y and W-
135) vaccine [MCV4] compared to no vaccination from a soci-
etal perspective. METHODS: A decision analysis model using
backward induction method was employed with parameter
values from published literature and HCUPnet (Health care Cost
and Utilization Project). All subjects were followed until they
reached 29 yr-old. Direct costs (vaccine, administration, hospi-
talization, outbreak control, and lifetime care) and indirect costs
(patient and health care workers time cost) were measured in
2005 US$. Effectiveness was measured as quality adjusted life
years [QALYs]. All costs and QALYs were discounted at 3% and
cost-effectiveness was measured as incremental cost per QALYs
gained [ICER]. Uncertainty was evaluated using multiple one-
way sensitivity analyses. RESULTS: All strategies yielded favor-
able ICERs ($16,746, $29,447, and $19,203 for 1st, 2nd, and
3rd strategy, respectively). The results were more favorable when
herd immunity was considered ($9916, $18,163, and $11,402
for 1st, 2nd, and 3rd strategy, respectively). All strategies were
highly sensitive to the duration of vaccine efﬁcacy and the dis-
count rate. A 50% decrease in these parameter values led to more
than a 100% change in ICERs. The herd immunity effect of
25%, 50%, and 75% lead approximately to 25%, 40%, and
50% change in ICERs. The model was sensitive to the disease
incidence rate, the risk for sequelae, and the vaccine cost, but
not to direct costs for treatment and the vaccine efﬁcacy. CON-
CLUSION: Three immunization strategies were cost-effective
compared to no vaccination using a societal threshold cut-off of
$50,000 per QALY. This analysis shows the opposite result to
previous U.S. ﬁndings. Further research is needed to explain
these discrepancies.
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OBJECTIVES: To examine the cost-effectiveness of PCV and to
determine if there is any long-term cost offset if it became a
routine vaccination for infants. METHODS: Two hypothetical
cohorts of 1000 infants (one vaccinated and one unvaccinated)
were followed over lifetime. A decision analytical model was
used to analyze the cost and cost-effectiveness of the vaccine
from a government’s perspective. The probabilities of events of
invasive pneumococcal diseases (IPD) and otitis media (OM)
were derived from published local or overseas data. Vaccine efﬁ-
cacy (mid-range) from overseas trials was used. Cost avoidance
arising from herd immunity was calculated based on overseas
published data. Cost of management of complications arising
from pneumococcal infections was estimated from a group of
hospitalized or outpatient cases from 2 large regional public hos-
pitals in Hong Kong. The costs associated with non-hospitalized
disease states were captured through interviews with a group of
identiﬁed GPs selected from different regions in Hong Kong. Vac-
cination programme costs included vaccine acquisition cost and
cost of administration. Productivity loss was assessed in terms of
extra care from family members, reduced earning ability and
early retirement due to disability, absenteeism, and premature
death. RESULTS: After a routine four-dose vaccination of infants
in their ﬁrst year of life, the PCV was estimated to have averted
566 cases of IPD and 2562 cases of OM. Using a discount rate
of 5% for all projections, the direct and indirect costs per life
year gained (CLYG) is HKD94,300 (USD12,090, 1USD =
7.8HKD) and HKD63,000 (USD8077) if no herd effect was
included. With herd immunity included, the direct and indirect
CLYG is reduced to HKD58,600 (USD7513) and HKD38,000
(USD4890) respectively. CONCLUSION: PCV appears to be
cost-saving by averting IPD and related complications and also
cost-effective due to herd immunity.
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OBJECTIVES: Evaluate the pharmacoeconomic impact of seven-
valent pneumococcal conjugate vaccine (Prevnar®) in a Cana-
dian population, accounting for herd immunity effects in
unvaccinated adults. METHODS: A cost-effectiveness analysis
was performed to compare costs and outcomes attributable to
invasive pneumococcal disease (IPD) and non-IPD in the periods
before (1998–2001) and after (2003–2005) the introduction of
Prevnar®. The main outcomes analyzed included total cases,
quality adjusted life years (QALY), and total cost for health
states bacteremia, meningitis, pneumonia, otitis media, myringo-
tomy, and death. Outcomes were based on real-world epidemi-
ology data from Calgary. Resource utilization was derived from
a Canadian Institute for Health Information database and, as
necessary, from the literature and expert opinion. All costs (in
2006 Canadian dollars) and outcomes were discounted by 3%.
